Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yi Chang Hec Dongyang Pharmaceutical
Yichang, Hubei, China
- Ownership
- Private
- Employees
- ~4500
- Development stage
- Other
01
Overview
Yi Chang Hec Dongyang Pharmaceutical is a leading Chinese pharmaceutical company specializing in anti-viral, endocrine, and metabolic diseases. It holds a dominant market share in China for oseltamivir (Kewei) and has successfully expanded into the insulin market with multiple approved biosimilar products.
- Therapeutic areas
- EndocrinologyNephrologyInfectious DiseasesMetabolic Disorders
- Modalities
- Small moleculeRecombinant proteinBiologic
- Industry
- Biotech
02
Partnerships
Taiho PharmaceuticalBlackstone
Beyond the preview
Go deeper on Yi Chang Hec Dongyang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yi Chang Hec Dongyang Pharmaceutical.